Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers

Journal of Pathology

Volumn 221, Issue 4, 2010, Pages 379-389

  Grotenhuis, Brechtje A ^a   Dinjens, Winand N M ^a   Wijnhoven, Bas P L ^a   Sonneveld, Petra ^a   Sacchetti, Andrea ^a   Franken, Patrick F ^a   Van Dekken, Herman ^a,b   Tilanus, Hugo W ^a   Van Lanschot, J Jan B ^a   Fodde, Riccardo ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Barrett's oesophagus; Cancer stem cells; Oesophageal adenocarcinoma; Tumour initiating cells

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA CATENIN; BETA1 INTEGRIN; CD133 ANTIGEN; CD24 ANTIGEN; CD44V ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER MODEL; CANCER STEM CELL; CLINICAL ASSESSMENT; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METAPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955476247     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2733     Document Type: Article

References (55)

1. Bremner CG, Lynch VP, Ellis FH Jr. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68: 209-216.
2. Paull A, Trier JS, Dalton MD, et al . The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-480.
3. Chandrasoma PT, Der R, Ma Y, et al . Histologic classification of patients based on mapping biopsies of the gastroesophageal junction. Am J Surg Pathol 2003; 27: 929-936.
4. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-1032.
5. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-993.
6. Jankowski JA, Wright NA, Meltzer SJ, et al . Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965-973.
7. Atherfold PA, Jankowski JA. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 2006; 20: 813-827.
8. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006; 55: 1810-1820.
9. Seery JP, Watt FM. Asymmetric stem-cell divisions define the architecture of human oesophageal epithelium. Curr Biol 2000; 10: 1447-1450.
10. Kalabis J, Oyama K, Okawa T, et al . A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest 2008; 118: 3860-3869.
11. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-859. (Pubitemid 15250200)
12. Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value? Endoscopy 1995; 27: 19-26.
13. Thomas T, Abrams KR, De Caestecker JS, et al . Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007; 26: 1465-1477.
14. Yousef F, Cardwell C, Cantwell MM, et al . The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-249.
15. Siewert JR, Stein HJ, Feith M, et al . Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-367; discussion, 368-369.
16. Lerut T, De Leyn P, Coosemans W, et al . Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992; 216: 583-590.
17. Cunningham D, Allum WH, Stenning SP, et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
18. Reya T, Morrison SJ, Clarke MF, et al . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
19. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006; 66: 1883-1890; discussion, 1895-1886.
20. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18: 460-466.
21. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
22. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anticancer therapy. FASEB J 2007; 21: 3777-3785. (Pubitemid 350232335)
23. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin Ther Targets 2007; 11: 915-927.
24. Cai J, Weiss ML, Rao MS. In search of 'stemness'. Exp Hematol 2004; 32: 585-598.
25. Natarajan TG, FitzGerald KT. Markers in normal and cancer stem cells. Cancer Biomark 2007; 3: 211-231.
26. Gokhale PJ, Andrews PW. A prospective on stem cell research. Semin Reprod Med 2006; 24: 289-297.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al . Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
28. O'Brien CA, Pollett A, Gallinger S, et al . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
29. Dalerba P, Dylla SJ, Park IK, et al . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163.
30. Bonnefoix T, Bonnefoix P, Verdiel P, et al . Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J Immunol Methods 1996; 194: 113-119.
31. Shackleton M, Vaillant F, Simpson KJ, et al . Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88.
32. Li C, Heidt DG, Dalerba P, et al . Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037. (Pubitemid 46270758)
33. Gao MQ, Choi YP, Kang S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; (in press).
34. Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150-158.
35. Ginestier C, Hur MH, Charafe-Jauffret E, et al . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
36. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362-371.
37. Haggitt RC. Pathology of Barrett's esophagus. J Gastrointest Surg 2000; 4: 117-118.
38. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004; 64: 1561-1569.
39. Zou H, Molina JR, Harrington JJ, et al . Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005; 116: 584-591.
40. Clement G, Jablons DM, Benhattar J. Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 2007; 11: 375-389. (Pubitemid 46290960)
41. Malanchi I, Peinado H, Kassen D, et al . Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 2008; 452: 650-653.
42. Washington K, Chiappori A, Hamilton K, et al . Expression of β-catenin, α-catenin and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998; 11: 805-813.
43. Bian YS, Osterheld MC, Bosman FT, et al . Nuclear accumulation of β-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000; 114: 583-590.
44. Osterheld MC, Bian YS, Bosman FT, et al . β-Catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002; 117: 451-456.
45. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35: 255-262.
46. Lim SC. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 2005; 59(suppl 2): S351-354.
47. Brakebusch C, Fassler R. β1 integrin function in vivo: adhesion, migration and more. Cancer Metast Rev 2005; 24: 403-411. (Pubitemid 41569980)
48. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-826.
49. Runz S, Mierke CT, Joumaa S, et al . CD24 induces localization of β1 integrin to lipid raft domains. Biochem Biophys Res Commun 2008; 365: 35-41.
50. Bottger TC, Youssef V, Dutkowski P, et al . Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. Cancer 1998; 83: 1074-1080.
51. Lagorce-Pages C, Paraf F, Dubois S, et al . Expression of CD44 in premalignant and malignant Barrett's oesophagus. Histopathology 1998; 32: 7-14. (Pubitemid 28122407)
52. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
53. Vermeulen L, Todaro M, de Sousa Mello F, et al . Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008; 105: 13427-13432.
54. Quintana E, Shackleton M, Sabel MS, et al . Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
55. Croagh D, Thomas RJ, Phillips WA, et al . Esophageal stem cells - a review of their identification and characterization. Stem Cell Rev 2008; 4: 261-268.